Security Snapshot

PLIANT THERAPEUTICS, INC. - Common Stock, par value $0.0001 per share (PLRX) Institutional Ownership

CUSIP: 729139105

13F Institutional Holders and Ownership History from Q2 2020 to Q1 2026

Latest Period

Q4 2025

Institutions Reporting

95

Shares (Excl. Options)

46,690,012

Price

$1.22

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.

Create free account to save this page Review latest holder period
Type / Class
Equity / Common Stock, par value $0.0001 per share
Symbol
PLRX on Nasdaq
Shares outstanding
61,399,727
Price per share
$1.27
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
46,690,012
Total reported value
$57,540,105
% of total 13F portfolios
0%
Share change
-5,596,219
Value change
-$7,125,150
Number of holders
95
Price from insider filings
$1.27
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Quick Takeaways

  • PLRX - PLIANT THERAPEUTICS, INC. - Common Stock, par value $0.0001 per share is tracked under CUSIP 729139105.
  • 95 institutions reported positions in Q4 2025.
  • 10 significant owners is listed from Schedule 13D/13G reporting.

What Changed

  • Holder count moved from 95 to 3 between Q4 2025 and Q1 2026.
  • Reported value moved from $57,540,105 to $142,209.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Source Evidence

Source: SEC Form 13F

Latest holder context comes from 95 institutions filings for Q4 2025.

Open SEC Evidence

Investment Quick Answers

What is CUSIP 729139105?
CUSIP 729139105 identifies PLRX - PLIANT THERAPEUTICS, INC. - Common Stock, par value $0.0001 per share in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.

Significant Owners of PLIANT THERAPEUTICS, INC. - Common Stock, par value $0.0001 per share (PLRX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
TANG CAPITAL MANAGEMENT LLC 9.6% $9,198,699 5,859,044 TANG CAPITAL MANAGEMENT, LLC 03 Mar 2025
CITADEL ADVISORS LLC 5% +2% $3,711,402 +$5,414 3,042,133 +0.15% Kenneth Griffin 02 Feb 2026
VANGUARD GROUP INC 4.9% $3,482,724 3,002,348 The Vanguard Group 30 Jun 2025
Redmile Group, LLC 4.8% $4,545,900 2,895,478 Redmile Group, LLC 31 Dec 2024
BlackRock, Inc. 3.4% $2,440,674 2,104,574 BlackRock, Inc. 30 Jun 2025
Woodline Partners LP 3.3% -57% $2,471,953 -$3,023,924 2,026,191 -55% Woodline Partners LP 31 Dec 2025
MORGAN STANLEY 0.9% -87% $861,460 -$5,043,529 545,228 -85% Morgan Stanley 31 Dec 2025
FMR LLC 0.2% $207,230 131,993 FMR LLC 28 Feb 2025
PRICE T ROWE ASSOCIATES INC /MD/ 0.1% $137,648 87,674 T. Rowe Price Associates, Inc. 31 Mar 2025
Point72 Asset Management, L.P. 0.1% -94% $56,775 -$4,926,946 46,537 -99% Point72 Asset Management, L.P. 31 Dec 2025

As of 31 Dec 2025, 95 institutional investors reported holding 46,690,012 shares of PLIANT THERAPEUTICS, INC. - Common Stock, par value $0.0001 per share (PLRX). This represents 76% of the company’s total 61,399,727 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of PLIANT THERAPEUTICS, INC. - Common Stock, par value $0.0001 per share (PLRX) together control 64% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
TANG CAPITAL MANAGEMENT LLC 10% 6,143,132 +2.3% 0.37% $7,494,621
Blue Owl Capital Holdings LP 4.8% 2,969,199 0% 1.1% $3,622,423
VANGUARD GROUP INC 4.6% 2,818,241 +1.5% 0% $3,438,255
CITADEL ADVISORS LLC 4.2% 2,583,332 +10% 0% $3,151,665
ACADIAN ASSET MANAGEMENT LLC 3.9% 2,364,669 -0.21% 0% $2,879,000
Woodline Partners LP 3.3% 2,026,191 -55% 0.01% $2,471,953
Monaco Asset Management SAM 3.2% 1,938,747 +136% 0.7% $2,365,271
Redmile Group, LLC 2.6% 1,616,228 +1.5% 0.15% $1,971,798
Prosight Management, LP 2.5% 1,555,744 +7494% 0.39% $1,898,008
BML Capital Management, LLC 2.5% 1,546,137 0% 1.7% $1,886,287
TWO SIGMA ADVISERS, LP 2% 1,245,600 +16% 0% $1,519,632
JPMORGAN CHASE & CO 2% 1,212,875 -43% 0% $1,479,707
MARSHALL WACE, LLP 1.8% 1,080,128 +261% 0% $1,317,756
BlackRock, Inc. 1.7% 1,073,272 -24% 0% $1,309,392
UBS Group AG 1.7% 1,062,615 -20% 0% $1,296,390
RENAISSANCE TECHNOLOGIES LLC 1.7% 1,045,818 +3.4% 0% $1,275,898
Centiva Capital, LP 1.6% 1,000,000 0.07% $1,220,000
TWO SIGMA INVESTMENTS, LP 1.6% 953,293 +22% 0% $1,163,017
Peapod Lane Capital LLC 1.4% 886,374 -19% 0.92% $1,081,376
Eversept Partners, LP 1.4% 842,023 +2.1% 0.06% $1,027,268
BANK OF AMERICA CORP /DE/ 1.2% 711,777 +0.53% 0% $868,368
JANE STREET GROUP, LLC 1.1% 653,774 +72% 0% $797,605
GSA CAPITAL PARTNERS LLP 1% 623,698 +288% 0.07% $761,000
GEODE CAPITAL MANAGEMENT, LLC 0.97% 592,696 +0.9% 0% $723,448
JACOBS LEVY EQUITY MANAGEMENT, INC 0.91% 556,938 +52% 0% $679,464

Institutional Holders of PLIANT THERAPEUTICS, INC. - Common Stock, par value $0.0001 per share (PLRX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 112,769 $142,209 -$1,124 $1.27 3
2025 Q4 46,690,012 $57,540,105 -$7,125,150 $1.22 95
2025 Q3 50,406,732 $74,592,710 +$1,536,181 $1.48 97
2025 Q2 51,491,424 $59,725,484 -$8,565,167 $1.16 112
2025 Q1 57,869,854 $78,126,006 -$216,549,992 $1.35 138
2024 Q4 64,754,179 $852,599,671 +$21,507,892 $13.17 158
2024 Q3 63,483,171 $714,277,363 -$5,607,911 $11.21 149
2024 Q2 63,896,951 $686,885,070 -$18,557,994 $10.75 141
2024 Q1 65,187,064 $971,256,923 +$41,504,855 $14.90 133
2023 Q4 62,712,668 $1,135,768,923 +$100,850,737 $18.11 133
2023 Q3 60,161,028 $1,043,150,835 +$29,447,949 $17.34 134
2023 Q2 58,042,121 $1,051,734,729 +$9,423,269 $18.12 141
2023 Q1 56,237,135 $1,495,380,265 +$312,862,520 $26.60 143
2022 Q4 44,702,851 $864,087,630 -$14,811,927 $19.33 123
2022 Q3 45,386,319 $948,113,021 +$327,405,105 $20.89 107
2022 Q2 30,133,558 $241,439,678 -$11,245,591 $8.01 81
2022 Q1 31,426,255 $220,339,413 +$4,111,275 $7.01 85
2021 Q4 30,850,148 $416,473,043 +$5,468,177 $13.50 81
2021 Q3 30,380,086 $512,798,759 -$14,863,235 $16.88 75
2021 Q2 30,676,131 $893,270,740 -$1,364,693 $29.12 80
2021 Q1 30,719,770 $1,208,139,215 +$88,069,181 $39.33 76
2020 Q4 28,511,470 $647,801,804 +$7,265,154 $22.72 57
2020 Q3 28,195,401 $635,735,229 +$17,040,139 $22.65 53
2020 Q2 26,908,341 $868,442,000 +$868,442,000 $32.46 36